Eight-year European cancer biomarker project receives €10m funding
This article was originally published in Clinica
The French innovation agency OSEO has injected €10m ($14.3m) into an eight-year research programme, IMAkinib, to develop specific biomarkers and radiotracers that would enable personalised and effective treatment for cancer patients. Heading the project, which is expected to cost €24.7m in total, is Oncodesign, a French oncology-focused biotech company. The firm will work together with fellow French companies Guerbet, which develops radiotracers for medical imaging procedures, and Ariana Pharmaceuticals, which specialises in data management software used to enhance the drug discovery and development process. Oncodesign will be responsible for developing the biomarkers specific to the drug treatments, while Guerbet will develop radiotracers. These radiotracers will be used in clinical trials for scanning tumours and to allow the evaluation of the drug's clinical efficacy. Ariana will provide the software for analysis of chemical and biological data.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.